SitemapContact Us
닫기
Search
Advanced Search +
닫기
Quick links
Most Cited Most Read Ahead of Print Archives Go to E-submission

Original Article

Split Viewer

Blood Res 2013; 48(2):

Published online June 25, 2013

https://doi.org/10.5045/br.2013.48.2.115

© The Korean Society of Hematology

Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry

Hyeon Gyu Yi1, Jin Seok Kim2, Cheolwon Suh3, Won Seog Kim4, Jae-Yong Kwak5, Jong-Seok Lee6, Yang Soo Kim7, Young Don Joo8, Yoo Hong Min2, Hong Ghi Lee9, Sung-Soo Yoon10, Jong-Ho Won11, Seonyang Park10, Hugh Chul Kim12, and Chul Soo Kim1*

Author Info. +

1Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.

2Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

3Department of Internal Medicine, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.

4Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

5Department of Internal Medicine, Chonbuk National University Medical School & Hospital, Jeonju, Korea.

6Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

7Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Pusan, Korea.

8Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Pusan, Korea.

9Department of Internal Medicine, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Korea.

10Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

11Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.

12Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea.

Korean Society of Hematology Lymphoma Working Party, Korea.

Correspondence to : Correspondence to Chul Soo Kim, M.D., Ph.D. Department of Internal Medicine, Inha University College of Medicine, 27, Inhang-ro, Jung-gu, Incheon 400-711, Korea. Tel: +82-32-890-2581, Fax: +82-32-890-2585, cskimmd@inha.ac.kr

Received: December 22, 2012; Revised: February 9, 2013; Accepted: May 17, 2013

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Go to

Background

This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes.

Methods

In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at and filed a total of 1,665 cases of DLBCL recorded since 1990.

Results

Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low- and low-intermediate-risk groups according to IPI scores significantly increased survival duration.

Conclusion

The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.

Keywords Diffuse large B-cell lymphoma, Epidemiology, Survival, Rituximab, CHOP regimen

Article

Original Article

Blood Res 2013; 48(2): 115-120

Published online June 25, 2013 https://doi.org/10.5045/br.2013.48.2.115

Copyright © The Korean Society of Hematology.

Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry

Hyeon Gyu Yi1, Jin Seok Kim2, Cheolwon Suh3, Won Seog Kim4, Jae-Yong Kwak5, Jong-Seok Lee6, Yang Soo Kim7, Young Don Joo8, Yoo Hong Min2, Hong Ghi Lee9, Sung-Soo Yoon10, Jong-Ho Won11, Seonyang Park10, Hugh Chul Kim12, and Chul Soo Kim1*

1Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.

2Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

3Department of Internal Medicine, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.

4Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

5Department of Internal Medicine, Chonbuk National University Medical School & Hospital, Jeonju, Korea.

6Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

7Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Pusan, Korea.

8Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Pusan, Korea.

9Department of Internal Medicine, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Korea.

10Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

11Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.

12Department of Internal Medicine, Ajou University School of Medicine, Suwon, Korea.

Korean Society of Hematology Lymphoma Working Party, Korea.

Correspondence to:Correspondence to Chul Soo Kim, M.D., Ph.D. Department of Internal Medicine, Inha University College of Medicine, 27, Inhang-ro, Jung-gu, Incheon 400-711, Korea. Tel: +82-32-890-2581, Fax: +82-32-890-2585, cskimmd@inha.ac.kr

Received: December 22, 2012; Revised: February 9, 2013; Accepted: May 17, 2013

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes.

Methods

In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at and filed a total of 1,665 cases of DLBCL recorded since 1990.

Results

Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low- and low-intermediate-risk groups according to IPI scores significantly increased survival duration.

Conclusion

The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.

Keywords: Diffuse large B-cell lymphoma, Epidemiology, Survival, Rituximab, CHOP regimen

Fig 1.

Download
Figure 1.

Comparison of OS in patients treated with CHOP vs. R-CHOP stratified according to risk: low-risk group (A), low-intermediate-risk group (B), high-intermediate-risk group (C), and high-risk group (D).

Blood Research 2013; 48: 115-120https://doi.org/10.5045/br.2013.48.2.115

Fig 2.

Download
Figure 2.

OS according to IPI (A) and aaIPI (B) scores for all patients. The log-rank P value for both indices was <0.001.

Blood Research 2013; 48: 115-120https://doi.org/10.5045/br.2013.48.2.115

Fig 3.

Download
Figure 3.

Predictive power of the IPI (A, B) and aaIPI (C, D) scoring systems for each treatment group. The log-rank P value for both indices was <0.001. Discrimination between the high-intermediate- and high-risk groups seemed to be difficult among patients treated with CHOP.

Blood Research 2013; 48: 115-120https://doi.org/10.5045/br.2013.48.2.115

Table 1 . Characteristics of the DLBCL patients..


Table 2 . Treatment outcomes of DLBCL patients..


Blood Res
Volume 59 2024
Current Issue Archives

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download